The pathogenesis and cellular origin of Langerhans cell histiocytosis (LCH) are debated. Recently, mutations on MAPK and PI3K pathways have been linked to disrupted cell proliferation in LCH. Janus Kinase 2 (JAK2) mutations play the same role in Philadelphia-negative chronic myeloproliferative neoplasms. We describe the case of a patient affected by JAK2-positive primary myelofibrosis (PMF) who developed a clonally related LCH while in treatment with ruxolitinib. JAK inhibitors are well known to affect function and differentiation of different hematological lineages, including mononuclear phagocytes precursors. Nevertheless, the literature describes cases of LCH clonally associated with non-LCH hematological neoplasm, suggesting how multilinear myeloid neoplasms may arise from bone marrow. Hence, we briefly discuss the possible pathogenic roles of genetic mutations and JAK inhibition therapy in the pathogenesis of LCH and associated neoplasms.

Bonometti, A., Bagnoli, F., Fanoni, D., Venegoni, L., Corti, L., Bianchi, P., et al. (2018). JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib. HUMAN PATHOLOGY, 73, 171-175 [10.1016/j.humpath.2017.10.017].

JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib

Elli E. M.;L'Imperio V.;Berti E.
2018

Abstract

The pathogenesis and cellular origin of Langerhans cell histiocytosis (LCH) are debated. Recently, mutations on MAPK and PI3K pathways have been linked to disrupted cell proliferation in LCH. Janus Kinase 2 (JAK2) mutations play the same role in Philadelphia-negative chronic myeloproliferative neoplasms. We describe the case of a patient affected by JAK2-positive primary myelofibrosis (PMF) who developed a clonally related LCH while in treatment with ruxolitinib. JAK inhibitors are well known to affect function and differentiation of different hematological lineages, including mononuclear phagocytes precursors. Nevertheless, the literature describes cases of LCH clonally associated with non-LCH hematological neoplasm, suggesting how multilinear myeloid neoplasms may arise from bone marrow. Hence, we briefly discuss the possible pathogenic roles of genetic mutations and JAK inhibition therapy in the pathogenesis of LCH and associated neoplasms.
Articolo in rivista - Articolo scientifico
JAK2; Langerhans cell histiocytosis; Laser microdissection; Multilineage myeloid neoplasms; Primary myelofibrosis; Ruxolitinib;
English
171
175
5
Bonometti, A., Bagnoli, F., Fanoni, D., Venegoni, L., Corti, L., Bianchi, P., et al. (2018). JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib. HUMAN PATHOLOGY, 73, 171-175 [10.1016/j.humpath.2017.10.017].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/349282
Citazioni
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 6
Social impact